<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1701">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004987</url>
  </required_header>
  <id_info>
    <org_study_id>21-00535</org_study_id>
    <nct_id>NCT05004987</nct_id>
  </id_info>
  <brief_title>Aβ Dynamics in LLMD</brief_title>
  <official_title>Depression Treatment and Aβ Dynamics: A Study of Alzheimer's Disease Risk (ABD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the biological factors that may modulate the relationship between&#xD;
      depression and the development of Alzheimer's disease (AD). Since the direction of causation&#xD;
      between depression and the biological factors associated with AD is unknown, the only way to&#xD;
      understand cause and associated risk is to treat the depressive symptoms and examine the&#xD;
      effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive&#xD;
      disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis&#xD;
      is that a reduction in depressive symptoms will be associated with a normalization of CSF AD&#xD;
      biomarkers as well as peripheral inflammatory markers. This research would contribute to&#xD;
      fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2022</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Both the study staff and the subjects will be blind to the study assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Vascular Dysfunction (VD) Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS)</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>MADRS consists of 10 items evaluating core symptoms of depression (e.g, apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, and suicidal thoughts). Each symptom is rated on a 0-6 scale (0=no abnormality, 6=severe). The total score ranges from 0 to 60; the higher the score, the more severe the symptoms.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Plasma Aβ Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) P-tau Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Cerebrospinal Fluid (CSF) T-tau Biomarker Levels</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Escitalopram (ESC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram Oxalate</intervention_name>
    <description>The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.</description>
    <arm_group_label>Escitalopram (ESC)</arm_group_label>
    <other_name>Lexapro</other_name>
    <other_name>ESC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily dose of placebo will mimic that of ESC.</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects, age 60+ years inclusive, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. Meeting Structured Clinical Interview (SCID-5-RV) for DSM-5 criteria for Major&#xD;
             depressive disorder.&#xD;
&#xD;
          3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥18.&#xD;
&#xD;
          4. Have results of a physical examination, neurological examination, vitals, and EKG&#xD;
             within normal limits at screening.&#xD;
&#xD;
          5. Cognitively unimpaired at screening visit as defined by Mini-Mental State Examination&#xD;
             (MMSE) &gt;27.&#xD;
&#xD;
          6. Clinical Dementia Rating Scale (CDR) Global of 0.&#xD;
&#xD;
          7. A score of 85 or greater on the RBANS delayed memory index score.&#xD;
&#xD;
          8. Fluent in English, because some of the instruments used in this study have not been&#xD;
             translated and validated in other languages, and are able to read at a 6th grade level&#xD;
             or equivalent, as determined by the PI.&#xD;
&#xD;
          9. Medically stable with no significant cerebrovascular, neurological, or systemic&#xD;
             disease expected to interfere with the study.&#xD;
&#xD;
         10. Adequate auditory acuity and normal-to-corrected vision.&#xD;
&#xD;
         11. Have a reliable and competent study partner who can accompany the subject to the&#xD;
             Screening Visit to verify absence of impairment in cognitive functions or activities&#xD;
             of daily living.&#xD;
&#xD;
         12. Willing to undergo brain MRI, urine drug screen and blood sampling for routine&#xD;
             laboratory testing, lumbar puncture, APOE genotyping and plasma drug levels.&#xD;
&#xD;
         13. Only individuals with normal hepatic and renal function including normal creatinine&#xD;
             clearance will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of brain tumor, MRI evidence of brain damage or brain disease including&#xD;
             significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white&#xD;
             matter hyperintensities.&#xD;
&#xD;
          2. Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease&#xD;
             or other movement disorders).&#xD;
&#xD;
          3. Subjects with a Fazekas scale &gt;2.&#xD;
&#xD;
          4. Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling&#xD;
             SCID-5-RV/DSM-5 criteria for current or past diagnosis of any psychiatric disorder&#xD;
             other than recurrent MDD including schizophrenia, bipolar disorder, dysthymic&#xD;
             disorder, panic disorder, agoraphobia, specific phobia, social phobia, obsessive&#xD;
             compulsive disorder, post-traumatic disorder, or any psychotic disorder.&#xD;
&#xD;
          5. A current significant risk for suicidality based on the Columbia-Suicide-Severity&#xD;
             Rating Scale (C-SSRS).&#xD;
&#xD;
          6. Insulin dependent diabetes.&#xD;
&#xD;
          7. Evidence of clinically relevant or unstable cardiac, pulmonary, endocrine or&#xD;
             hematological conditions.&#xD;
&#xD;
          8. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard&#xD;
             for MRI imaging.&#xD;
&#xD;
          9. Positive urine drug screen for illicit drugs.&#xD;
&#xD;
         10. History of poor tolerance to, poor response to, or ongoing treatment with&#xD;
             escitalopram.&#xD;
&#xD;
         11. If taking antidepressants, currently taking fluoxetine, due to the length of time&#xD;
             required to washout.&#xD;
&#xD;
         12. Currently taking medications potentially affecting cognition other than SSRIs;&#xD;
             narcotic analgesics,chronic use of medications with anticholinergic activity,&#xD;
             Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine,&#xD;
             pergolide, selegiline).&#xD;
&#xD;
               -  Others medications that are exclusionary include: amphetamines, amphetamine-like&#xD;
                  compounds, appetite suppressants, phenothiazines, reserpine, buspirone,&#xD;
                  clonidine, disulfiram, guanethidine, theophylline, melatonin, salicylates,&#xD;
                  cholinesterase inhibitors and memantine. Continuous aspirin (any dosage) use and&#xD;
                  St. John's Wort are excluded.&#xD;
&#xD;
               -  For subjects taking antidepressants at screening, no dosage changes for ≥3&#xD;
                  months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nunzio Pomara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antero Sarreal, MD</last_name>
    <phone>845-398-6532</phone>
    <email>Antero.sarreal@nki.rfmh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chelsea Reichert Plaska, PhD</last_name>
    <phone>845-398-5583</phone>
    <email>Chelsea.reichert@nki.rfmh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nunzio Pomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antero Sarreal, MD</last_name>
      <phone>845-398-6532</phone>
      <email>Antero.sarreal@nki.rfmh.org</email>
    </contact>
    <investigator>
      <last_name>Nunzio Pomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>February 8, 2022</last_update_submitted>
  <last_update_submitted_qc>February 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to nunzio.pomara@nki.rfmh.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

